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ABSTRACT
Objective: Aerobic exercise can improve cardiovascular
fitness and does not seem to be detrimental to patients
with asthma, though its role in changing asthma control
and inflammatory profiles is unclear. The main hypothesis
of the current randomised controlled trial is that aerobic
exercise will be superior to usual care in improving
asthma control. Key secondary outcomes are asthma
quality of life and inflammatory profiles.
Design: A total of 104 sedentary adults with physician-
diagnosed asthma will be recruited. Eligible participants
will undergo a series of baseline assessments including:
the asthma control questionnaire; the asthma quality-of-
life questionnaire and the inflammatory profile (assessed
from both the blood and sputum samples). On
completion of the assessments, participants will be
randomised (1:1 allocation) to either 12-weeks of usual
care or usual care plus aerobic exercise. Aerobic exercise
will consist of three supervised training sessions per
week. Each session will consist of taking a short-acting
bronchodilator, 10 min of warm-up, 40 min of aerobic
exercise (50–75% of heart rate reserve for weeks 1–4,
then 70–85% for weeks 5–12) and a 10 min cool-down.
Within 1 week of completion, participants will be
reassessed (same battery as at baseline). Analyses will
assess the difference between the two intervention arms
on postintervention levels of asthma control, quality of life
and inflammation, adjusting for age, baseline inhaled
corticosteroid prescription, body weight change and
pretreatment dependent variable level. Missing data will
be handled using standard multiple imputation
techniques.
Ethics and dissemination: The study has been
approved by all relevant research ethics boards. Written
consent will be obtained from all participants who will be
able to withdraw at any time.
Results: The result will be disseminated to three groups
of stakeholder groups: (1) the scientific and professional
community; (2) the research participants and (3) the
general public.
Registration Details ClinicalTrials.gov Identifier:
NCT00953342
INTRODUCTION
Asthma is a chronic disorder of the airways
characterised by reversible and intermittent
airway obstruction and airway inﬂammation
in response to a variety of stimuli (eg, pollen,
dust, animal hair, smoke and airborne pollu-
tants). Asthma is among the four most
common chronic disorders affecting
Canadian adults1 2 with over 2.5 million
(8.5%) adults being diagnosed as having
asthma.3 More importantly, asthma is an escal-
ating medical problem in Canada, with a 40%
increase in asthma incidence in the last two
decades.3 4 Furthermore, the rates of poor
asthma control have also increased, with
nearly 60% of Canadian patients being poorly
controlled.5 6 These increases have come
despite important advances in diagnosis and
treatment,7–11 suggesting that these changes
in asthma must be multifactorial.12 Cytokines
have been shown to play a critical role in
orchestrating, perpetuating and amplifying
the inﬂammatory response in asthma. Among
these cytokines, interleukin (IL)-1, tumour
necrosis factor (TNF)-α and IL-6 are involved
in chronic airway diseases, while IL-4, IL-5,
IL-9 and IL-13, which are mainly derived
from T helper type (Th)-2 cells, are more spe-
ciﬁc to allergic inﬂammation.13 IL-4 is an
upstream cytokine that regulates allergic
inﬂammation by promoting Th2 cell differen-
tiation and immunoglobulin (Ig) G switching
to IgE subsequently, whereas IL-5 is highly
speciﬁc for inducing eosinophilic inﬂamma-
tion.13 Similar to IL-4, IL-13 regulates IgE pro-
duction but, unlike IL-4, it does not regulate
T cell differentiation to Th2 cells.14 Thus, the
increased and abnormal expression of cyto-
kines in airways is one of the major features
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of allergic asthma. Recent reports have indicated that
stimulating Th1 cells (IL-2 and interferon (IFN)-γ) might
suppress Th2 cells, and thereby allergic inﬂammation.15
Therefore, the balance between Th1 and Th2 is import-
ant for immunoregulation, with imbalance believed to
cause allergic asthma, and may predict the chronicity and
the severity of asthma. However, recent ﬁndings indicate
that the overall picture is more complex. For instance,
both endogenous and inducible CD4+CD25+ regulatory
T cells, through the release of IL-10, inhibit inappropriate
immune responses in Th1/Th2 balance.16
A recent Cochrane review on physical training
(aerobic exercise intervention of at least 20 min twice a
week for 4 weeks) and asthma (which included articles
up to April 2011)17 reported the following key ﬁndings:
▸ Training improved cardiopulmonary ﬁtness as mea-
sured by a statistically and clinically signiﬁcant
increase in maximum oxygen uptake;
▸ Training had no signiﬁcant effect on resting lung
function;
▸ None of the studies reported a worsening of asthma
symptoms following training;
▸ Training may have a positive effect on health-related
quality of life.
These ﬁndings lead the authors to conclude that “…
training can improve cardiopulmonary ﬁtness and was
well tolerated among people with asthma” and that this
can be performed ‘… without fear of symptom exacerba-
tion.”17 However, it should be noted that only 19 studies
(695 participants) were included in the review, and
overall these studies were of low quality with a high risk
of bias. As such, it would seem that aerobic exercise is
safe, increases ﬁtness, does not change lung function,
and may improve quality of life. With regard to asthma
symptoms, only one of the seven studies reporting on
symptoms actually used a recognised questionnaire (the
Asthma Control Questionnaire (ACQ)18) to assess symp-
toms,19 with no changes seen between the exercise or
control interventions. However, a small randomised con-
trolled trial, which was published after the Cochrane
review, found that aerobic exercise was associated with a
statistical and clinical improvement in control in patients
with asthma. These ﬁndings suggest that still more work
needs to be done to understand the effects of exercise
in symptom management and asthma control. Finally,
though not the focus of the Cochrane review, one of the
included studies found that aerobic exercise had a posi-
tive impact on inﬂammation in patients with asthma.
Using induced sputum cell counts, Mendes et al20
reported decreases in eosinophils in the exercise group
compared with the control group. While this result sug-
gests a beneﬁt of aerobic exercise, the data are still too
limited to come to any solid conclusions.
ORIGINALITY AND IMPORTANCE OF THE RESULTS
The therapeutic role of exercise training has been estab-
lished for various chronic conditions (eg, heart disease,
chronic obstructive pulmonary disease (COPD), type II
diabetes, etc) such that this non-pharmacological inter-
vention is now included in several disease management
guidelines. To our knowledge, the proposed research
project will be one of the ﬁrst to systematically evaluate
the beneﬁts of aerobic exercise training on asthma
control, and the potential for inﬂammation to underpin
such beneﬁts, in adult asthma patients. The results of this
study will add to the current evidence base for physicians
to prescribe aerobic exercise for patients with asthma.
Research hypothesis
Aerobic exercise will be superior to usual care in the




To determine if, in comparison to usual care, a 12-week
supervised aerobic exercise programme improves




To determine if, in comparison to usual care, a 12-week
supervised aerobic exercise programme improves
asthma quality of lifeE and inﬂammatory proﬁles in
patients with stable physician-diagnosed asthma.
Other secondary objectives
To assess potential inﬂammatory mechanisms linking
aerobic exercise and improved asthma control.
METHODS AND ANALYSIS
Trial design
The ex-asthma study trial is designed as a randomised,
controlled, observer-blinded multicentre superiority trial
with two parallel groups and a primary end point of
asthma control ( Juniper questionnaire) in the week fol-
lowing the intervention period. Randomisation will be
performed with a 1:1 computer generated allocation.
Study setting
To ensure that an objective physician diagnosis of
asthma, and to increase the probability of detecting a
higher level of poor asthma control, patients will be pri-
marily recruited from the outpatient asthma clinics at
Hôpital du Sacré-Cœur de Montréal (HSCM), the
Montreal Chest Institute and the Jewish General
Hospital. All sites are based in Montreal to ensure ease
of oversight in the delivery of the study.
Eligibility criteria
Patients must provide written informed consent before
any study procedures are performed. To determine eligi-
bility and the stability of the patients’ asthma control
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and medication, potential participants will undergo a
4-week screening period.
Inclusion criteria:
1. Physician-diagnosed asthma (conﬁrmed by medical
record evidence of bronchodilator reversibility of
12% or PC20 methacholine ≤16 mg/mL);
2. Sedentary (currently do less than 60 min of struc-
tured/planned physical activity per week);
3. Taking at least 250 mg ﬂuticasone equivalent per day;
4. On stable dose and regimen of asthma medications;
5. Mild-to-moderate symptomatic asthma as deﬁned by
an ACQ score of 1.25 or greater.21
Exclusion criteria:
1. Diagnosed comorbid disease for which there are
already established exercise guidelines, that is,
cardiac disease or COPD;
2. Any other medical condition that confers greater
illness morbidity than asthma (eg, active cancer)
which will be conﬁrmed by physician review;
3. Forced expiratory volume in 1 s (FEV1) lower than
60% of predicted;
4. Incapable of exercising;
5. A body mass index >30 kg/m2;
6. Unable to speak or understand either French or
English;
7. <18 years of age
8. Patients who are currently pregnant or intend to
become pregnant over the course of the study.
Interventions
Aerobic exercise intervention
The exercise intervention will start within a week of
completing the ﬁnal baseline assessment. Participants
will exercise three times/week at a level of 50–75% of
their initial heart rate reserve determined at the time
of the baseline exercise test for the ﬁrst 4 weeks, and
then progress to 70–85% of their heart rate reserve for
the remaining 8 weeks.22 Patients will be required to
take their reliever medication (short-acting bronchodila-
tor) approximately 15 min prior to starting the exercise
session (as per the GINA guidelines8) to reduce the
chances of exercise-induced bronchospasm. The exer-
cise routine will consist of 10 min of warm-up exercises,
40 min of biking and/or walking (and eventually
jogging) and 10 min of cool-down exercises. Emphasis
will be placed on ensuring that patients cool down
properly as this is the time when most exercise-induced
bronchospasm (EIB) events would potentially
occur.23–26 A trained exercise physiologist (Canadian
Sport and Exercise Physiologist certiﬁed or equivalent)
will supervise all exercise sessions, and will perform
three checks of heart rates per session to ensure that
participants are exercising at a sufﬁcient intensity. In
general, this exercise programme follows the guidelines
for patients with chronic illnesses (eg, patients with
heart disease and COPD).27 28 In total, we offer six
time slots per week (3 in the morning before work and
3 in the afternoon after work). All participants will be
required to maintain their normal medical regimens
during the intervention. Exercise sessions will be con-
ducted at either the Centre de readaptation
Jean-Jacques Gauthier, HSCM or within the pulmonary
rehabilitation programme, Montreal Chest Institute.
Usual medical care comparison group
Patients in the usual medical care control comparison
group will be asked to refrain from any structured
exercise (ie, maintain their current behaviour) for
12 weeks until they are re-evaluated. During this
12-week period, we will contact patients every 4 weeks
to assess asthma symptoms, events, medication adher-
ence and check to see if they have started or intend to
start exercising. Based on our previous studies, only
about 1% of control participants actively engage in
exercise.29 To ensure equity to all our patients, partici-
pants in the comparison group will be given the
opportunity to participate in the exercise programme
once they have completed the post-trial assessments.
No assessments will be made following the cross-over
exercise period.
Adherence to the exercise protocol
We will take the following steps to maximise adherence
to the interventions: (1) Careful screening: we will
thoroughly review our protocol and emphasise the
importance of recruiting motivated participants who
are ready to embark upon a sustained exercise pro-
gramme. (2) Thorough orientation: participants will
receive detailed information about the rationale and
potential beneﬁts of the programme. (3) Behavioural
contracts: a written contract will be signed by the par-
ticipant at the time of the initial orientation. In this
contract, the patient will agree to participate in the
programme to the best of their abilities, and to discuss
any concerns or difﬁculties with the study coordinator
before considering dropping out of the programme.
(4) Close exercise supervision: during the exercise ses-
sions, we will closely supervise exercising participants
to ensure that they exercise within their prescribed
training ranges. In addition, the participants’ heart
rate will be consistently monitored so that patients
who fall below or who exceed their respective training
ranges can be identiﬁed and their exercise modiﬁed.
This approach has been used successfully in our prior
work.29 These strategies have been successful in our
prior exercise studies employing patients with chronic
diseases, where the dropout rates were <5%.29
Concomitant care
As both arms of the study will be receiving the usual
medical care, all potential addition treatment options
are available to the patient’s regular physicians.
However, if there are any additional medical interven-
tions, they will be noted in the patient’s chart.
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OUTCOMES
Primary outcome measure
Differences between the two treatment arms in the abso-
lute change asthma control postintervention will be
assessed using the ACQ.18 ACQ evaluates asthma control
by asking respondents to recall their symptoms (includ-
ing nocturnal awakenings), activity limitation and bron-
chodilator use in the last week. An additional question
assessing FEV1, % predicted, is completed by the
research assistant. It contains seven items rated on a
seven-point scale (0=good control, 6=poor control). It
has high intraclass correlation coefﬁcients (0.90–0.95)
and good construct, cross-sectional and longitudinal val-
idity.18 30 31 It has also been shown that a score greater
than 0.8 is associated with poor control,21 and a change
or difference of ≥0.5 in ACQ has clinical signiﬁcance.31
ACQ will be administered within 1 week of the comple-
tion of the intervention.
Secondary outcomes measures
In addition to ACQ, absolute differences in the Asthma
Control Test (ACT)32 33 will be used as a secondary
measure of asthma control. ACT evaluates levels of asthma
control according to standard criteria speciﬁed by inter-
national guidelines:34 activity limitations, shortness of
breath, nocturnal or waking symptoms, bronchodilator use
and perceived control over the past 4 weeks. It contains ﬁve
items rated on a ﬁve-point scale (with higher scores indicat-
ing better control). ACT has also demonstrated excellent
measurement properties, including good internal consist-
ency (α=0.79–0.85), test–retest reliability (α=0.77) and
excellent criterion validity with ACQ (r=−0.89). A score of
≤19 on this questionnaire is indicative of poor asthma
control.33 ACT will be administered within 1 week of the
completion of the intervention.
Differences between the two treatment arms in the
absolute change in asthma-related quality of life postin-
tervention will be assessed by the Asthma Quality of Life
Questionnaire (AQLQ).35 AQLQ assesses the extent to
which asthma limits the asthmatic’s life or interferes with
their ability to do and/or enjoy different activities typical
of daily life. AQLQ has 32 items rated on a seven-point
Likert scale from 1 (a great deal) to 7 (not at all). It has
four subscales: activity limitation, symptoms, environment
and emotional distress. It has high intraclass correlation
coefﬁcients (0.90–0.95) and good construct, cross-
sectional and longitudinal validity.35–37 It has also been
shown that a change or difference of ≥0.5 in AQLQ has
clinical signiﬁcance.38 AQLQ will be administered within
1 week of the completion of the intervention.
Differences between the two treatment arms in inﬂam-
matory proﬁles postintervention will be assessed using a
variety of sputum-based and blood-based markers.
Sputum will be induced by the method described by
Pin et al39 and modiﬁed by that of Pizzichini et al40
Brieﬂy, participants will be pretreated with 200 μg of sal-
butamol before inhaling increasing concentrations of
hypertonic saline (3%, 4% and 5%) for 7 min each (for
a maximum of 21 min) with a Medix electronic nebu-
liser (Medix, Catthorp, England) without a valve or nose
clip. After each inhalation, participants will be instructed
to blow their nose, rinse their mouth and swallow the
water to minimise postnasal drip and squamous epithe-
lial cell contamination, respectively, before trying to
expectorate in a sterile container. The mucus that will
be obtained will then be separated from the saliva using
forceps, weighed and rocked with four times its volume
of dithiothreitol (Sputolysin; Calbiochem Corp., La
Jolla, California, USA) for 15 min. The reaction will be
stopped by adding an equal volume of Dulbecco’s
phosphate-buffered saline (D-PBS) 1×(Invitrogen,
Burlington, Ontario, Canada). The cellular suspension
will then be centrifuged at 8000 rpm for 4 min and the
supernatant will be collected and frozen at −80°C for
further analysis. The cells will then be resuspended in
D-PBS 1× and slides will be prepared with a Cytospin 3
(Shandon Scientiﬁc Ltd, Astmoor, England) and col-
oured with Diff-Quik solutions (Dade Diagnostics Inc,
Aguada, Puerto Rico, USA) for a count of 400 cells.
Sputum supernatants will be concentrated using Amicon
columns before assessing the mediator’s quantiﬁcation,
as described previously.41 The sputum supernatant
eosinophil cationic protein (a marker of eosinophils
activation) and neutrophil-derived myeloperoxidase
(a marker of neutrophils activation) will be determined
by ELISA (BioSource, Medicorp).41 The Th2 cytokines,
IL-4, IL-13, IL-10, the Th1 cytokines, IL-2, IFN-γ, IL-12
and the acute inﬂammatory cytokines IL-6 and TNF-α
will be determined using a mutiplex bead array cytokine
assay and Luminex technology.42 The Bio-Plex system
(Bio-Rad) was recently acquired by our research group
from a CIHR grant (# PRG 80172). Bio-Plex cytokine
kits and complementary kits (eg, a Bio-Plex cytokine
reagent kit) will allow the simultaneous quantiﬁcation of
several human cytokines in a single 10–25 mL biological
sample with an extended dynamic range compared with
ELISA. Cytokines will be measured according to the
manufacturer’s instructions. Using standard hospital pro-
cedures, blood draws will be made following a 20-min
rest period via the insertion of an 18-gauge needle into
the anterior cubital vein of the non-dominant arm.
A 5 cc of blood will be drawn into tubes, and the serum
will be collected and stored at, 80 C until assayed for
cytokines levels (see details below). In addition, 5 cc of
blood will be drawn into heparinised tubes for differen-
tial white cell counts, conducted on a Coulter STKS
counter.
Other notable outcomes
As a series of manipulation checks and based on previ-
ous studies, we are anticipating that there will be a post-
intervention difference in exercise capacity between the
two intervention groups but no difference in lung
function.43 44
As per the guidelines,45 all participants will undergo
standard ﬁtness evaluations using an electrically braked
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cycle ergometer (Collins CPX Bike model 0070; Warren
E Collins; Braintree, Massachusetts, USA) following the
Jones protocol.46 Participants will exercise to exhaustion
(fatigue, leg pain or shortness of breath). Expired air
will be collected through the mouthpiece of a calibrated
screen pneumotachograph (Collins/Cybermedic model
003500; Warren E Collins) and into an O2 and CO2 ana-
lyser (Quinton Qplex; A-H Robins, Bothel, Washington,
USA). The pneumotachograph will be located 5 cm
from the mouth and will be calibrated using the
American Thoracic Society standards.47 As per standard
practice,27 48 minute ventilation (VE), oxygen uptake
(VO2) and CO2 excretion (VCO2) will be analysed on a
breath-by-breath basis, with minute averages being
obtained during the rest period (2 min of standing) and
exercise test. To decrease the chances of patients having
an EIB, all participants will be required to take their
reliever medication 15 min prior to starting the exercise
and will participate in active recovery/cool down.
Airway responsiveness to methacholine will be assessed
according to the methods described previously.49 Aerosols
will be generated by a Wright nebuliser at 344 Kpa and
8 L min in order to get an output of 0.13 mL min. The
aerosol will be inhaled by tidal breathing, with a face-mask
held loosely over the face and a noseclip. Half-doubling
concentrations of methacholine (from 0.03 to
128 mg/mL) will be inhaled for 2 min at 5 min intervals,
until a fall of at least 20% of the FEV1. Airway responsive-
ness will be expressed as the PC20 methacholine obtained
from the log dose–response curve.
Standard pulmonary function tests, including spirom-
etry, lung volumes and diffusion capacity, will be
obtained according to previously described guide-
lines.47 50 For the assessments, rescue (bronchodilator)
medication will be withheld for at least 4 h before pul-
monary function tests are performed. FEV1 and forced
vital capacity will be assessed before and 15 min after
the administration of 200 μg salbutamol using a
metered-dose inhaler or 500 µg terbutaline using a
Turbuhaler. All results will be related to standard normal
values.51–54
Additional measures
To be able to appropriately describe our population,
and in parallel with our previous research,55–57 we will
collect basic demographic and medical information,
most notable of which will be age, which will be used for
determination of eligibility. In addition, health beha-
viours (smoking status,58 diet habits59 and sleep60), eth-
nicity, marital status, socioeconomic status (years of
education, income, occupation and residential depriv-
ation61 62), gender role63 and anthropometrics (height,
weight, and waist and hip circumference) will also be
collected. The self-reported details of current and life-
time histories of asthma, other respiratory diseases, car-
diovascular disease (CVD), CVD risk factors, cancers
and auto-immune diseases, as well as all current medica-
tions will be collected. We will also administer the
Morisky Self-Rated Measure of Medication Adherence
questionnaire,64 which is a validated measure of medica-
tion adherence.65 It will be used to assess inhaled cor-
ticosteroid adherence. In addition, we will ask if patients
are currently pregnant or intend to become pregnant
over the course of the study for exclusion purposes. All
reported clinical data will be veriﬁed by a hospital
medical record review.
Participant timeline
The aerobic exercise intervention will start within
1 week of completion of the baseline assessments and
the usual care intervention will commence on comple-
tion of the baseline assessments. The follow-up assess-
ments will be the same as those completed at baseline
and will occur within 1 week of the end of the interven-
tion, that is, 13 weeks after the baseline assessments.
However, to ensure there are no carry-over effects of
acute exercise bouts, all postintervention measures will
be assessed after a minimum of 24 h of inactivity (recov-
ery).66 See ﬁgure 1 for a schematic of the study.
Sample size
We have based our sample size calculations on data that
we have already collected from participants who were
recruited from the asthma clinic at HSCM. Using data
from our current epidemiological sample55–57 and the
inclusion/exclusion criteria detailed above, we estab-
lished that for the current eligible group, the baseline
mean±SD ACQ score would be 2.14±0.86. Using a stand-
ard 2 group design with equal variance and setting
power at 0.8, p=0.05, and two-sided hypothesis testing,
Figure 1 Schematic of
participant timeline.
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a decrease of 0.5 in the ACQ score (this change has
been shown to be clinically signiﬁcant31) would require
a sample size of 47/group, for a total sample of 94.
Using the same criteria, we established that the baseline
mean±SD AQLQ score for the eligible group is
4.60±0.91, and using the same parameters, a clinically
signiﬁcant increase of 0.538 in AQLQ would require a
sample size of 52 patients/group for a total sample size
of 104. To deal with the issue of compliance and drop-
outs, as recommended by the CONSORT statement,67
we will use intent-to-treat analyses.68 Use of the
intent-to-treat analyses preserves the effects of group
allocation and provides an assessment of the practical
impact of a treatment. As there are no data on the
effects of exercise training on immune markers in
asthma patients, and few clinical guidelines on which to
base expected changes, we have used published data
from a previous study in a diseased population. Like
asthma, heart disease is also considered a disease of
immune dysfunction; as such, using data generated by
Goldhammer et al69 for an exercise training intervention
on coronary heart disease patients seems to be an
adequate estimation of the immune effects we may see
in asthma patients. For example, setting a power of 0.8,
and p=0.05, the required sample size to see a similar
outcome in the current study for IL-1, IL-6 and INF-γ
would be 34, 36 and 78, respectively. All these sample
size estimates are within the proposed sample size
of 104.
Recruitment
The primary recruitment site will be HSCM (ca. 70% of
participants) with the other two sites each contributing
about 15% of the total required participants. All three
sites will use patient lists for those attending asthma or
pneumology clinics to identify potentially eligible
patients to approach; in general, each site sees over 20
asthma patients per week. In addition, the HSCM site
will use a pre-existing database of over 800 tertiary care
asthma patients,55–57 from which eligible patients will be
contacted, and local advertising via newspapers and
radio to the general public.
Each participant will receive modest ﬁnancial compen-
sation (100 CAD) for participation. For participants who
drop out, payments will be pro-rated for the length of
time they stayed in the study.
Assignment of interventions
Allocation and blinding
Participants will be randomly assigned to either the
control or experimental group with a 1:1 allocation as
per a computer generated randomisation schedule strati-
ﬁed by site and patient sex. To ensure allocation con-
cealment, the randomisation will be handled by a
member of staff not directly associated with recruitment,
assessment or intervention delivery. The randomisation
code will not be released until the patient has com-
pleted all baseline assessments. The staff member will
provide a letter detailing the randomisation to the par-
ticipant and will inform the interventionists of the
patient’s group allocation. None of the staff responsible
for conducting assessments will be provided details of
the allocation. In addition, all participants are asked to
not indicate their assignment to any member of staff
other than the interventionist they are working with. If a
member of the assessment team is informed by the
patient, they will remove themselves from any further
assessment of that participant. As such, the participant
and intervention staff will not be blinded to the group
allocation, but the assessment staff will be.
Retention
Once randomised, a participant will be considered as
being included in the study. Once all postintervention
assessments have been completed (irrespective of adher-
ence to the protocol), a participant will be consider to
have completed the study. Based on our previous work
with similar exercise interventions,29 we estimate that
the rate of loss to follow-up will be 5%.
Participant withdrawal
Participants may withdraw from the study for any reason
at any time. The senior investigator of the research
project or the local ethics committee may withdraw the
participant if new information or discoveries indicate
that their participation in the project is not in their
interest, if they do not follow the guidelines of the
research project, or if there are administrative reasons to
abandon the project.
Data management
Data forms and data entry
All data will be entered electronically using Microsoft
Access. This will be carried out at either HSCM or MCI,
depending on where the data originated. Original study
forms will be entered and kept on ﬁle at the participat-
ing site. All data will be entered into two parallel elec-
tronic databases (double entry). Participant ﬁles are to
be stored in numerical order and stored in a secure and
accessible place and manner. Participant ﬁles will be
maintained in storage for a period of 25 years after com-
pletion of the study. All blood and sputum samples will
be stored in the HSCM tissue bank for an initial period
of 5 years following analyses.
Data transmission and editing
The data entry screens will resemble the paper forms.
Data integrity will be managed using referential data
rules, valid values and using pull-down menus for
certain categorical codes. Checks will be applied at the
time of data entry into a speciﬁc ﬁeld.
Data discrepancy inquiries
Additional errors will be detected by using SAS proc
compared with detecting missing data or speciﬁc errors
between the two electronically created datasets. These
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errors will be summarised along with detailed descrip-
tions for each speciﬁc problem in Data Query Reports.
The research assistant who receives the inquiry will
respond by checking the original forms for inconsist-
ency, checking other sources to determine the correc-
tion, modifying the original (paper) form and updating
the two electronic datasets.
Security and back-up of data
All forms related to study data will be kept in locked
cabinets. Access to the study data will be restricted.
A complete back-up of the two electronic databases will
be performed daily by the respective research centres.
In addition, back-ups onto local external hard drives will
be conducted weekly.
Study status reports
A monthly report on recruitment, study participations
and completion will be provided to the study PI.
Proposed statistical analyses
Primary outcome
A general linear model will be used with the postinter-
vention ACQ score as the dependent variable, treatment
group as the between participant factor and age, base-
line inhaled corticosteroid prescription (as a proxy of
asthma severity), body weight change and pretreatment
ACQ scores as covariates. Prior to conducting the ana-
lyses, preliminary examination of the assumptions of the
analysis of covariance model will be conducted.
Particular attention will be given to homogeneity of
regression assumption, violations of heteroscedasticity of
errors and non-linearity. Should these assumptions be
violated, we will use interaction terms or appropriate
transformation as necessary.
Secondary analyses
In parallel to the primary outcome, a series of general
linear models will be used to assess intervention effects
on ACT, AQLQ and the inﬂammatory markers. With the
exception of substituting the pretreatment ACQ levels
with the pretreatment levels of the dependent variable,
all other covariates will be the same.
As deﬁned by Baron et al70 71 and adapted by Kraemer
et al72 73 for two group studies, a series of mediator ana-
lyses, with Sobel testing, will be conducted to explore
inﬂammatory changes as a mechanism linking exercise
to improved asthma control. To accomplish this, we will
use a two-step regression model approach. In step 1,
a simple general linear model (GLM) regression will be
conducted with change in exercise (deﬁned as the dif-
ference in postintervention VO2 minus preintervention
VO2) as the independent variable and change in asthma
control (deﬁned as post minus preintervention levels) as
the dependent variable. The above deﬁned covariates,
plus intervention group will be included. In step 2, the
change in inﬂammatory markers, as well as the inter-
action between the change in VO2 and the change in
inﬂammatory markers, will be included as additional
independent variables, with the change in asthma
control as the dependent variable and the above covari-
ates. It should be noted that each inﬂammatory marker
will be included in a separate set of analyses. In these
kinds of analyses, a main or interaction effect of the
inﬂammatory marker in step 2 would indicate that that
particular marker mediated the relationship between
exercise and asthma control.72 These kinds of analyses
may not provide us with deﬁnitive causal and/or mech-
anistic relationships but will allow us to further expand
our knowledge in the area.
p Value reporting will be consistent with the require-
ments of the place where the results will be published.
Up-to-date versions of SAS (Cary, North Carolina,
USA) will be used to conduct analyses. For all tests, we
will use two-sided p values with an α≤0.05 level of signiﬁ-
cance. Multiple tests will be corrected with Benjamini
and Hochberg’s False Discovery Rate correction proced-
ure.74–76
Analysis population and missing data
All main analyses will use intention-to-treat, considering
all patients as randomised regardless of their adherence
to the treatment protocol or completion of postinterven-
tion assessments. These analyses will be used to deﬁne
the efﬁcacy of aerobic exercise to inﬂuence asthma
control. However, consistent with other behavioural
trials, we will also conduct a series of completer analyses
(ie, inclusion of only those with complete preinterven-
tion and postintervention assessment data). These will
be conducted as quasisensitivity analyses. Given our
expectation that very few patients will be lost to
follow-up, these analyses should agree very closely.
Imputation procedure for missing data
We will report reasons for withdrawal for each random-
isation group and compare the reasons qualitatively.
Incomplete postintervention assessment data will be
included in the analysis by modern imputation methods
for missing data.77 78 The main feature of the approach
is the creation of a set of clinically reasonable imputa-
tions for the respective outcome for each dropout. This
will be accomplished using a set of repeated imputations
created by predictive models based on the majority of
participants with complete data. The imputation models
will reﬂect uncertainty in the modelling process and
inherent variability in patient outcomes, as reﬂected in
the complete data. After the imputations are completed,
all the data (complete and imputed) will be combined
and the analysis performed for each imputed-and-
completed dataset. Rubin’s method of multiple (ie,
repeated) imputation will be used to estimate the treat-
ment effect. We propose to use ﬁve datasets. Analyses
will follow Harrell’s guidelines78 and will use the mul-
tiple imputation procedure available in SAS (SAS Inc,
North Carolina, USA).
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Data monitoring and interim analyses
Owing to the small size of the trial and the relatively
short study duration, no data monitoring committee will
be established and no interim analyses will be
conducted.
Harm
In our study, an adverse event will be deﬁned as any
untoward medical occurrence in a participant without
regard to the possibility of a causal relationship. Adverse
events will be collected after the participant has pro-
vided consent and enrolled in the study. All adverse
events occurring after entry (signing of a consent form)
into the study and until completion of postintervention
assessments or study withdrawal will be recorded. An
adverse event that meets the criteria for a serious
adverse event (SAE) will be reported to the local
Research Ethics Board (REB) as an SAE. An SAE for
this study is any untoward medical occurrence that is
believed by the investigators to be causally related to par-
ticipating in the study and results in any of the following:
life-threatening condition (ie, immediate risk of death);
severe or permanent disability or prolonged hospitalisa-
tion. SAEs occurring after a participant has discontinued
from the study will NOT be reported unless the investi-
gators feel that the event may have been caused by the
study. Investigators will determine the relatedness of an
event to the study intervention or procedure based on a
temporal relationship, as well as whether the event is
unexpected or unexplained given the participant’s clin-
ical course, previous medical conditions and concomi-
tant medications. All SAEs will be reported for the trial
and if there is sufﬁcient power to assess intervention dif-
ferences, a general linear model (see above) will be
conducted.
Auditing
There will be no additional ongoing auditing of the data




The Ex-asthma study has been approved by the HSCM
(ID: 2009–09–61) and McGill University Health Centre
(ID: 10–076-BMC) REB. This approval covers the
consent forms, all study procedures and assessments,
recruitment scripts and advertising material. All study
related documents, with the exception of the protocol,
were approved in both French and English. The study
complies with all REB policies and guidelines.
Subsequent to the initial review and approval, the
responsible local REB will review the protocol and pro-
gress reports (including safety) at least annually. In add-
ition, within 12 months of study completion, the
investigative team will provide each local REB with a
ﬁnal report.
Modifications of the protocol
Any modiﬁcations to the protocol which may impact on
the conduct of the study, potential beneﬁt of the patient
or affect patient safety, including changes of study objec-
tives, study design, patient population, sample sizes, study
procedures or signiﬁcant administrative aspects, will
require a formal amendment to the protocol. Such
amendment will be agreed upon by the investigative team
and approved by the REBs prior to implementation.
Obtaining informed consent
Trained rsesearch assistants will introduce the trial to
patients who will be shown a printed powerpoint presen-
tation regarding the main aspects of the trial. They will
discuss the trial with patients in light of the information
provided. The patients will then be able to have an
informed discussion with the participating consultant.
Research assistants will obtain written consent from the
patients willing to participate in the trial. All information
and consent forms are provided in both French and
English.
Confidentiality
All study-related information will be stored securely at
the study sites. All participant information will be stored
in locked ﬁle cabinets in areas with limited access. All
laboratory specimens, reports, data collection, process
and administrative forms will be identiﬁed by a coded
identiﬁcation number only to maintain participant con-
ﬁdentiality. All local databases will be secured with
password-protected access systems.
Access to data
All ﬁnal data will be stored centrally and all analyses will
be conducted through the research team at HSCM. All
investigators and students will have the capacity to
request ancillary analyses.
Ancillary and post-trial care
No additional ancillary or post-trial care will be provided
beyond the usual care covered by the Quebec provincial
healthcare plan.
Knowledge translation strategy for trial results
The scientiﬁc integrity of the project requires that the
data from all sites be analysed study-wide and reported
as such. Substantive contributions to the design,
conduct, interpretation and reporting of a clinical trial
are recognised through the granting of authorship on
the ﬁnal trial report. The ﬁndings of this trial will be dis-
seminated to a number of stakeholder groups.
The scientiﬁc and professional community, dissemination
to this community will be performed through traditional
channels of presentations at scientiﬁc meetings, grand
rounds and publication of journal articles in open-access
internet format as well as traditional publications.
Research participants, individuals who participate in the
research will all receive personalised letters summarising
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Table 1 SPIRIT trial registration dataset80
Data category Information
Primary registry and trial
identifying number
ClinicalTrials.gov Identifier: NCT00953342
Date of registration in primary
registry
4 August 2009
Secondary identifying numbers MOP93807
Source(s) of monetary or
material support
Canadian Institutes of Health Research
Primary sponsor Canadian Institutes of Health Research
Secondary sponsor(s) Concordia University, Hôpital du Sacré-Cœur de Montréal
Contact for public queries SLB
Contact for scientific queries SLB
Public title Impact of Aerobic Exercise on Asthma Morbidity (Ex-asthma study)
Scientific title Impact of Aerobic Exercise on Asthma Morbidity (Ex-asthma study)




Intervention(s) Active comparator: 12 weeks of supervised aerobic exercise and standard carePlacebo
comparator: 12 weeks of standard care
Key inclusion and exclusion
criteria
Inclusion criteria:
▸ Physician-diagnosed asthma (confirmed by medical record evidence of bronchodilator
reversibility of 12% or a minimum of 180 cc or PC20 methacholine ≤16 mg/mL)
▸ Sedentary (currently do less than 60 min of structured/planned physical activity per
week)
▸ Taking at least 250 mg fluticasone equivalent per day
▸ On stable dose and regimen of asthma medications
▸ Mild-to-moderate symptomatic asthma as defined by an Asthma Control Questionnaire
score of 1.25 or greater
Exclusion criteria:
▸ Diagnosed comorbid disease for which there are already established exercise
guidelines, that is, cardiac disease or COPD
▸ Any other medical condition that confers greater illness morbidity than asthma (eg,
active cancer) which will be confirmed by physician review
▸ FEV1 lower than 60% of predicted
▸ Incapable of exercising
▸ A BMI>30 kg/m2
▸ Unable to speak or understand either French or English
▸ <18 years of age




Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: single blind (outcomes assessor)
Primary purpose: treatment
Phase III
Date of first enrolment January 2010
Target sample size 104
Recruitment status Recruiting
Primary outcome(s) Asthma control Questionnaire ( Juniper) ( time frame: within 1 week of completion of the
intervention (ie, after 12 weeks)
Key secondary outcomes ▸ Asthma quality of life questionnaire ( Juniper) ( time frame: within 1 week of completion
of the intervention (ie, after 12 weeks))
▸ Asthma control test (time frame: within 1 week of completion of the intervention (ie, after
12 weeks))
▸ Inflammatory markers (time frame: within 1 week of completion of the intervention (ie,
after 12 weeks))
Of note, a full SPIRIT checklist is provided as a supplementary file.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s.
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their own personal results in the trial, as well as the
overall results. These will be presented to participants at
an end-of-study reception where printed results of the
study will be distributed and explained.
General public, media will be invited to the participants’
reception to ﬁlm and interview the researchers
about the study results, as well as any participants who
provide such consent. A study website has been created
(accessible via the Montreal Behavioural Medicine
Centre website (http://mbmc-cmcm.ca/en/projects/Ex-
Asthma.php)) that describes the study and recruitment.
On completion of the study, photographs of the
end-of-study reception and press releases as well as
downloads of scientiﬁc papers will be posted. The lay
press will also be targeted to publish lay summaries of
the study ﬁndings (table 1).
Authorship policy
In general, named authorship for all secondary abstracts
and papers will be deﬁned as per the guidelines of the
International Committee of Medical Journal Editors.79
Wherever possible, after the inclusion of all named
authors, the author list will be completed with … “for
the Ex-Asthma Study Group, with the full list of investi-
gators provided in an appendix”.
Public access to the full protocol, participant-level dataset
and statistical code
There are currently no plans to post the protocol,
de-identiﬁed dataset or statistical code on a public access
data archive for sharing purposes. However, the investi-
gators would be happy to discuss data sharing with inter-
ested researchers.
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